EVOKE PHARMA, INC. Financing Receivable, Credit Loss, Expense (Reversal)
EVOKE PHARMA, INC. reported Financing Receivable, Credit Loss, Expense (Reversal) of $0 for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ProvisionForLoanLossesExpensed · last filed 2025-11-13
- EVOKE PHARMA, INC. financing receivable, credit loss, expense (reversal) for the quarter ending 2025-09-30 was $0.00.
- EVOKE PHARMA, INC. financing receivable, credit loss, expense (reversal) for the quarter ending 2025-06-30 was $0.00.
- EVOKE PHARMA, INC. financing receivable, credit loss, expense (reversal) for the quarter ending 2025-03-31 was $0.00.
- EVOKE PHARMA, INC. financing receivable, credit loss, expense (reversal) for the quarter ending 2024-09-30 was $0.00.
| Period end | Financing Receivable, Credit Loss, Expense (Reversal) 3 month | Financing Receivable, Credit Loss, Expense (Reversal) 6 month | Financing Receivable, Credit Loss, Expense (Reversal) 9 month |
|---|---|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-13 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-13 |